Melinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million ~

NEW HAVEN, Conn., Dec. 19, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that it has received a commitment from Vatera Healthcare Partners LLC and its affiliates (collectively, “Vatera”) for a convertible loan facility in the amount of up to of $135 million, with the option to be converted into preferred shares at an exercise price of $1.60 per share, representing a 39 percent premium to the Company’s closing share price on December 18, 2018.